Bacil Pharma [BACPHAR] vs Sequent Scientific [SEQUENT] Detailed Stock Comparison
Bacil Pharma
BSE
Loading...
Sequent Scientific
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Bacil Pharma wins in 10 metrics, Sequent Scientific wins in 7 metrics, with 0 ties. Bacil Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bacil Pharma | Sequent Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 30.00 | 151.30 | Bacil Pharma |
| Price-to-Book Ratio | 1.13 | 6.17 | Bacil Pharma |
| Debt-to-Equity Ratio | 0.64 | 62.47 | Bacil Pharma |
| PEG Ratio | -0.03 | 1.27 | Bacil Pharma |
| EV/EBITDA | -153.41 | 29.08 | Bacil Pharma |
| Profit Margin (TTM) | 111.61% | 1.85% | Bacil Pharma |
| Operating Margin (TTM) | -10.86% | 7.56% | Sequent Scientific |
| EBITDA Margin (TTM) | N/A | 7.56% | N/A |
| Return on Equity | 1.59% | 2.84% | Sequent Scientific |
| Return on Assets (TTM) | 1.58% | 1.37% | Bacil Pharma |
| Free Cash Flow (TTM) | $4.01M | $442.73M | Sequent Scientific |
| 1-Year Return | 92.79% | 3.51% | Bacil Pharma |
| Price-to-Sales Ratio (TTM) | 21.92 | 2.71 | Sequent Scientific |
| Enterprise Value | $487.13M | $48.30B | Sequent Scientific |
| EV/Revenue Ratio | 49.12 | 3.01 | Sequent Scientific |
| Gross Profit Margin (TTM) | N/A | 46.86% | N/A |
| Revenue per Share (TTM) | $1 | $64 | Sequent Scientific |
| Earnings per Share (Diluted) | $1.23 | $1.15 | Bacil Pharma |
| Beta (Stock Volatility) | 0.30 | 0.91 | Bacil Pharma |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Bacil Pharma vs Sequent Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bacil Pharma | -1.60% | -1.60% | -1.81% | -11.19% | -11.53% | -30.72% |
| Sequent Scientific | -0.42% | -3.68% | -4.25% | -12.89% | 13.97% | -8.28% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bacil Pharma | 92.79% | 766.20% | 1,146.62% | 476.56% | 638.00% | 246.48% |
| Sequent Scientific | 3.51% | 47.92% | 26.44% | 14.88% | 14.88% | 14.88% |
Performance & Financial Health Analysis: Bacil Pharma vs Sequent Scientific
| Metric | BACPHAR | SEQUENT |
|---|---|---|
| Market Information | ||
| Market Cap | ₹217.34M | ₹43.49B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 29,436 | 314,145 |
| 90 Day Avg. Volume | 31,562 | 529,689 |
| Last Close | ₹36.90 | ₹169.37 |
| 52 Week Range | ₹16.24 - ₹62.56 | ₹117.35 - ₹240.70 |
| % from 52W High | -41.02% | -29.63% |
| All-Time High | ₹62.56 (Dec 16, 2024) | ₹336.50 (Jun 28, 2021) |
| % from All-Time High | -41.02% | -49.67% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.13% |
| Quarterly Earnings Growth | N/A | 1.20% |
| Financial Health | ||
| Profit Margin (TTM) | 1.12% | 0.02% |
| Operating Margin (TTM) | -0.11% | 0.08% |
| Return on Equity (TTM) | 0.02% | 0.03% |
| Debt to Equity (MRQ) | 0.64 | 62.47 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹32.60 | ₹28.19 |
| Cash per Share (MRQ) | ₹2.05 | ₹2.52 |
| Operating Cash Flow (TTM) | ₹4.03M | ₹360.47M |
| Levered Free Cash Flow (TTM) | ₹4.04M | ₹218.78M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Bacil Pharma vs Sequent Scientific
| Metric | BACPHAR | SEQUENT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 30.00 | 151.30 |
| Forward P/E | N/A | 34.46 |
| PEG Ratio | -0.03 | 1.27 |
| Price to Sales (TTM) | 21.92 | 2.71 |
| Price to Book (MRQ) | 1.13 | 6.17 |
| Market Capitalization | ||
| Market Capitalization | ₹217.34M | ₹43.49B |
| Enterprise Value | ₹487.13M | ₹48.30B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 49.12 | 3.01 |
| Enterprise to EBITDA | -153.41 | 29.08 |
| Risk & Other Metrics | ||
| Beta | 0.30 | 0.91 |
| Book Value per Share (MRQ) | ₹32.60 | ₹28.19 |
Financial Statements Comparison: Bacil Pharma vs Sequent Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BACPHAR | SEQUENT |
|---|---|---|
| Revenue/Sales | ₹0 | ₹4.41B |
| Cost of Goods Sold | N/A | ₹2.35B |
| Gross Profit | N/A | ₹2.07B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-1.09M | ₹333.50M |
| EBITDA | ₹-1.09M | ₹505.30M |
| Pre-Tax Income | ₹8.94M | ₹255.20M |
| Income Tax | ₹2.25M | ₹79.50M |
| Net Income (Profit) | ₹6.69M | ₹175.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BACPHAR | SEQUENT |
|---|---|---|
| Cash & Equivalents | ₹28.57M | ₹626.60M |
| Total Current Assets | ₹29.08M | ₹8.74B |
| Total Current Liabilities | ₹1.69M | ₹5.05B |
| Long-Term Debt | N/A | ₹3.00B |
| Total Shareholders Equity | ₹254.31M | ₹7.70B |
| Retained Earnings | N/A | ₹1.25B |
| Property, Plant & Equipment | N/A | ₹2.84B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BACPHAR | SEQUENT |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BACPHAR | SEQUENT |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 29,436 | 314,145 |
| Average Daily Volume (90 Day) | 31,562 | 529,689 |
| Shares Outstanding | 5.89M | 249.89M |
| Float Shares | 12.10M | 117.77M |
| % Held by Insiders | 0.15% | 0.53% |
| % Held by Institutions | 0.00% | 0.13% |
Dividend Analysis & Yield Comparison: Bacil Pharma vs Sequent Scientific
| Metric | BACPHAR | SEQUENT |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |